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Abstract
Background: The aim of this study was to determine if hypertensive type 2 diabetic patients, when
compared to patients with essential hypertension have an increased left ventricular mass index
(LVMI) and a worse diastolic function, and if this fact would be related to 24-h pressoric levels
changes.
Methods: Ninety-one hypertensive patients with type 2 diabetes mellitus (DM) (group-1 [G1]), 59
essential hypertensive patients (group-2 [G2]) and 26 healthy controls (group-3 [G3]) were
submitted to 24-h Ambulatory Blood Pressure Monitoring (ABPM) and echocardiography (ECHO)
with Doppler. We calculated an average of fasting blood glucose (AFBG) values of G1 from the
previous 4.2 years and a glycemic control index (GCI) (percentual of FBG above 200 mg/dl).
Results: G1 and G2 did not differ on average of diurnal systolic and diastolic BP. However, G1
presented worse diastolic function and a higher average of nocturnal systolic BP (NSBP) and LVMI
(NSBP = 132 ± 18 vs 124 ± 14 mmHg; P < 0.05 and LVMI = 103 ± 27 vs 89 ± 17 g/m2; P < 0.05,
respectively). In G1, LVMI correlated with NSBP (r = 0.37; P < 0.001) and GCI (r = 0.29; P < 0.05)
while NSBP correlated with GCI (r = 0.27; P < 0.05) and AFBG (r = 0.30; P < 0.01). When G1 was
divided in tertiles according to NSBP, the subgroup with NSBP≥140 mmHg showed a higher risk
of LVH. Diabetics with NSBP≥140 mmHg and AFBG>165 mg/dl showed an additional risk of LVH
(P < 0.05; odds ratio = 11). In multivariate regression, both GCI and NSBP were independent
predictors of LVMI in G1.
Conclusion: This study suggests that hyperglycemia and higher NSBP levels should be responsible
for an increased prevalence of LVH in hypertensive patients with Type 2 DM.
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Background
Clinical, epidemiologic and pathological data support the
occurrence of a specific cardiomyopathy related to diabe-
tes mellitus (DM) [1-3]. However, the exact cause of this
complication is still being discussed. Proposed causes
include metabolic abnormalities (hyperglycemia and
changes in myocardial lipid metabolism), hypertension
and autonomic neuropathy [3-6]. As DM is usually asso-
ciated to hypertension and coronary arteriosclerosis [2]
and they all can reduce myocardial performance, it's hard
to dissociate cardiac abnormalities (LVH and diastolic
dysfunction) originated from those conditions to that
straightly related to metabolic changes of DM.
In 1992, Grossman et al [7], showed that hypertensive
patients with DM, when compared to essential hyperten-
sive patients, had a higher LVMI independent of office
blood pressure. The principal determinant of the BP circa-
dian pattern appears to be the sympathetic nervous sys-
tem and DM has been associated with elevated levels of
nocturnal BP [8]. We have demonstrated that the
improvement of glycemic control may play an independ-
ent role in the reversal of LVH in hypertensive patients
with type 2 DM [9]. Nevertheless, in our study, 24-h BP
levels were not evaluated.
The purpose of this study was to determine if hypertensive
type 2 diabetic patients, when compared to patients with
essential hypertension have an increased LVMI and a
worse diastolic function, and if this fact would be related
to 24-h pressoric levels changes.
Methods
Patients
A total of 176 subjects recruited from our Hypertension
Clinic during one year period were enrolled in this study.
The 91 (64 women and 27 men) hypertensive patients
with type 2 DM (group-1 [G1]), the 59 (46 women and 13
men) nondiabetic hypertensive patients (group-2 [G2])
and the 26 healthy control subjects (group-3 [G3]) were
submitted to 24-h ABPM and to ECHO with Doppler to
evaluate LVMI and diastolic function. ABPM was done
after a 15 days washout of all antihypertensive drugs in
order to evaluate patient's real blood pressure and mini-
mize the effect of BP variations during the long period of
cardiac hypertrophy development. Ten patients of G1
couldn't have their LVMI measured because of technical
problems (narrow window: obesity); the other 81 remain-
ders were divided in 3 subgroups (tertiles) based on their
NSBP to stablish the prevalence of LVH. G1 had the fol-
lowing parameters calculated: the average of fasting blood
glucose (AFBG) values and the glycemic control index
(GCI).
All patients had normal levels of serum creatinine and
only two had abnormal 24-h urinary protein excretion
(>150 mg/24h). Patients with clinical or echocardio-
graphic evidence of ischemic or valvular heart disease
were not included in this study, nor were those with con-
gestive heart failure, alcoholism or secondary or severe
hypertension. Criteria for established hypertension were
systolic and diastolic blood pressure≥140/90 mmHg on
repeated measurements [10]. Diabetes was diagnosed
according to the standart criteria [11]. Type 2 DM were
indentified as those with disease onset at the age of 30
years or after with no need of insulin treatment. They were
treated only with diet or diet plus oral antidiabetic agents
(sulphonylureas, metformin, or acarbose) and antihyper-
tensive drugs. None of them was treated with insulin dur-
ing the study. This study was approved by the Institutional
Ethics Committee.
Echocardiography
M-mode, two-dimensional echocardiographic and car-
diac Doppler studies were performed using a commer-
cially available echo-Doppler unit (Esaote Biomedica,
Florence, Italy; model SIM 5000) equipped with a 2.5-
MHz mechanical transducer. It was performed with
patients in the partial left lateral supine position. M-mode
measurements were performed acording to the recom-
mendations of the American Society of Echocardiography
[12]. Left ventricular mass (LVM) was calculated as previ-
ously recommended by Deveraux et al [13]. The LVMI was
calculated by dividing LVM by the body surface area. LVH
was present if LVMI was ≥134 g/m2 in men and ≥110 g/m2
in women [13,14]. All examinations were analyzed
blindly by one independent echocardiographer. Transmi-
tral blood flow signals were obtained on top of mitral
valve by apical 4-chamber-view and the following meas-
urements were made on consecutive cardiac cycles: (1)
peak flow velocity of early left ventricular (LV) filling
(peak E), (2) peak flow velocity of late (atrial) LV filling
(peak A), (3) early deceleration time (DT), (4) isovolumic
relaxation period (IVR) and (5) the ratio between early
and late diastolic flow velocity peaks (E/A ratio) (normal
values: peak E>50 cm/s; peak A<80 cm/s; DT<240 ms;
IVR<110 ms, and E/A ratio≥1) [15,16]. All measurements
of diastolic function were done with normal heart rate
(60–100 bpm).
Ambulatory Blood Pressure Monitoring
The 24-hour ABPM recording was performed using a Spa-
ceLabs – 90207 automatic cuff-oscillometric device (Spa-
celabs, Inc. Redmond, WA – USA) after 15 days washout
of all antihypertensive drugs. Patients should keep their
habitual routine and present a report with the activities
done. Systolic and diastolic BP and heart rate were
recorded at 15-minutes intervals during daytime and
nighttime periods. Daytime period included all activitiesCardiovascular Diabetology 2006, 5:19 http://www.cardiab.com/content/5/1/19
Page 3 of 7
(page number not for citation purposes)
done from 8am to 8pm and the 8pm to 8am period was
considered nighttime. After this, the average of systolic
and diastolic BP was calculated for each hour, for daytime,
nighttime and for the 24-hour period. The exam was con-
sidered reliable when at least 75% of the measurements
were successfully executed. Moreover, it was calculated the
nocturnal BP decrease ([diurnal systolic blood pressure -
nocturnal systolic blood pressure] × 100/diurnal systolic
blood pressure). It was considered normal values of noc-
turnal BP decrease greater than 10% (dippers) and
patients that showed BP decrease lower than this value
were called "nondippers". We used the absolute values of
NSBP instead of nocturnal BP fall to divide the subgroups
in tertiles because the first variable has a minor coefficient
of variation (data not published).
Other measurements
To create a measure of the previous long-term glycemic
control, the average of all fasting blood glucose (AFBG)
values available before the study was calculated (mean
period of 4.2 years and mean of 3.7 values of FBG/patient/
year). A total of 1014 FBG were evaluated. If several FBG
were recorded during a month, only the first value of the
month was used. These FBG values were also used to cal-
culate the glycemic control index (GCI) (percentual of
FBG values above 200 mg/dl).
Statistical analysis
All normally distributed values were given as mean ± SD
and all other values were given as median (range). In com-
parisons of the nonnormally distributed variables, the
Kruskal-Wallis test on variance was used to test the differ-
ences between the three groups. If differences were found,
the Mann-Whitney test was used for comparisons
between two groups. For all normally distributed varia-
bles, analysis of variance was performed to test the differ-
ences among the three groups. If differences were found,
the Student's t test was used for comparison between two
groups. Fisher's exact or chi-squared tests for trend have
been used to compare categorical data. For correlation
analysis, correlation coefficients (Pearson or Spearman)
were calculated. For regression analysis (forward stepwise
regression), in a first model, the LVMI was used as a
dependent variable and age, sex, body mass index (BMI),
NSBP, GCI and diabetes and hypertension duration were
used as independent variables. A second model of regres-
sion analysis was used with NSBP as dependent variable
and age, BMI, AFBG and DM and hypertension duration
as independent variables. A P value (two-tailed) less than
0.05 was considered statistically significant. All calcula-
tions were made with a commercially available program,
SigmaStat 1.0 (Jandel Scientific Corporation, Chicago,
Illinois).
Results
Clinical characteristics of the three groups are in table 1.
In G1, the AFBG was 156 ± 41 mg/dl and duration of dia-
betes was 48 months (5 – 456). We also evaluated the
antihypertensive drugs used during the year before the
study. We found that diabetics, when compared to essen-
tial hypertensives, used more frequently ACE-inhibitors
(30% vs 13%; P < 0.05; odds ratio = 2.9) and calcium
antagonists (46% vs 15%; P < 0.05; odds ratio = 4.7) than
others antihypertensive drugs (diuretics, beta-blockers,
etc) (24% vs 72%; P < 0.05; odds ratio = 8.0).
G1 and G2 did not differ in age, BMI, sex, duration of
hypertension and average of diurnal systolic and diastolic
BP, however healthy control subjects (G3) differed in
diurnal BP levels when compared to G1 and G2 (table 1).
There was no difference between office BP of diabetic
hypertensive patients and nondiabetic hypertensive
patients as well.
According to table 2, G1 presented higher NSBP and
LVMI. Patients with DM also presented a worse diastolic
function (DT and peak A) (table 2). Additionally, when
compared G1 and G2, the first group showed more sub-
jects with abnormal values of DT (45% vs 15%; P < 0.001;
odds ratio = 3.4) and peak A (40% vs 16%; P < 0.05; odds
ratio = 2.6).
In G1, LVMI correlated to NSBP (r = 0.37, P < 0.01) and
GCI (r = 0.29, P < 0.05), while NSBP correlated to GCI (r
= 0.27, P < 0.05) and AFBG (r = 0.30, P < 0.01).
When G1 was divided in tertiles according to NSBP (table
3), the subgroup with NSBP≥140 mmHg showed a higher
risk of LVH (P < 0.001, odds ratio = 7.5 when compared
to patients with NSBP≤124 mmHg and P < 0.01, odds
ratio = 3.8 when compared to patients with NSBP between
124 and 140 mmHg). In the subgroup with NSBP≥140
Table 1: Clinical characteristics of study population
Group Sex (M/F) Age (years) BMI (kg/m2) Duration of EH (months) DSBP (mmHg) DDBP (mmHg)
G1 27/64 57 ± 9 28 ± 4 144 (3 – 612) 146 ± 19 90 ± 12
G2 13/46 54 ± 10 27 ± 4 120 (1 – 420) 140 ± 13 90 ± 9
G3 11/15 55 ± 8 27 ± 5 - 122 ± 10* 77 ± 8*
*P < 0.05 G3 vs G1 and G2
DDBP = diurnal diastolic BP; DSBP = diurnal systolic BP; EH = essential hypertensionCardiovascular Diabetology 2006, 5:19 http://www.cardiab.com/content/5/1/19
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mmHg, patients with LVH (n = 15) did not differ of
patients with normal LVMI (n = 12), according to age,
hypertension duration, NSBP and diurnal BP, however
they presented a higher GCI (table 4). Furthermore, dia-
betics with NSBP≥140 mmHg and AFBG>165 mg/dl
showed an additional risk of LVH (P < 0.05; odds ratio =
11) (figure 1).
In G1, the first model of multivariate regression showed
both GCI and NSBP as independent predictors of LVMI
(r2 = 0.11; P < 0.01 and r2 = 0.08; P < 0.01, respectively).
In the second model, only hypertension duration was an
independent predictor of NSBP (r2 = 0.11, P < 0.01).
Discussion
The present study demonstrated that hypertensive
patients with type 2 DM when compared to patients with
essential hypertension presented higher NSBP and LVMI.
These findings occurred independently of sex, age, BMI
and diurnal BP levels. We have also found a worse diasto-
lic function in diabetic patients.
Grossman et al [7], comparing hypertensive type 2 DM
patients with essential hypertensives also found a higher
LVMI in the first group. Nevertheless, they didn't evaluate
the 24-h BP levels. We have confirmed these data and
have showed that in hypertensives with type 2 DM, the
NSBP could be a new important co-factor, that in addition
to hyperglycemia, would be responsible for a higher prev-
alence of LVH in these patients.
Palmieri et al [17], evaluating almost 400 hypertensive
diabetic patients in comparison with essential hyperten-
sive, have found that the first group had higher LVM inde-
pendently of BP levels. Furthermore, Tenenbaum et al
[18] also described that type 2 DM was associated with a
higher prevalence of LVH in hypertensive women but not
in men. Finally, Galderisi et al [19], evaluating 1986 men
and 1519 women from the original Framingham Study
cohort, in a multivariate model, concluded that DM is an
independent contributor to LVM. Nevertheless, all these
authors have not performed ABPM in their studies.
There are several mechanisms that could be responsible
for a lower fall of BP during sleep. Some authors have
associated it to diabetic nephropathy (DN) [20] that
could be explained by an increase of extracellular fluid
[21]. In our study, only 2 of 91 diabetics had abnormal
proteinuria and all of them had normal creatinine levels.
Therefore, DN couldn't justify elevated NSBP in our
group. According to Rutter et al [22], LVH is more com-
mon and severe in those with microalbuminuria and its
presence may be related to raised night/day systolic blood
pressure ratio. Nevertheless we have not done microalbu-
minuria in our patients.
Patients with type 2 DM are more stable in blood glucose
control than patients with type 1 DM [23] and FBG has
been commonly used to monitor glycemic control in type
2 diabetic patients treated with diet alone or oral hypogly-
Table 3: Clinical parameters of diabetic hypertensive patients (G1) based on their NSBP
Group NSBP≤124 mmHg 124< NSBP < 140 NSBP≥140 mmHg
N 2 72 72 7
Age (years) 56 ± 11 58 ± 7 58 ± 8
BMI (kg/m2) 28 ± 5 28 ± 4 29 ± 4
DDBP (mmHg) 81 ± 8 88 ± 10 101 ± 9†
NDBP (mmHg) 67 ± 6 78 ± 6 87 ± 8†
DSBP (mmHg) 13 ± 28 143 ± 11 168 ± 17†
NSBP (mmHg) 115 ± 4 131 ± 4 154 ± 15†
SBPD (%) 12 ± 5 8 ± 7* 8 ± 6*
LVMI (g/m2) 93 ± 30 101 ± 23 114 ± 24*
LVH (yes/no) 2/25 4/23 15/12*‡
AFBG 150 ± 45 158 ± 38 168 ± 31
† P < 0.05 between the three groups; * P < 0.05 vs NSBP≤124 mmHg; ‡ P < 0.05 vs 124< NSBP < 140
DDBP = diurnal diastolic BP; DSBP = diurnal systolic BP; NDBP = nocturnal diastolic BP;
SBPD = systolic BP decrease
Table 2: Nocturnal BP recording and ECHO with Doppler 
results in study population
Group G1 G2 G3
N9 1 5 9 2 6
NSBP (mmHg) 132 ± 18‡ 124 ± 14 108 ± 11
NDBP (mmHg) 77 ± 10* 75 ± 98* 64 ± 8
LVMI (g/m2) 103 ± 27*† 89 ± 17 82 ± 14
LVH (%) 26* 14 0
DT (ms) 236 ± 58*† 198 ± 49 199 ± 34
IVR (ms) 98 ± 20* 101 ± 27* 83 ± 17
E/A ratio 0.84 (0.3 – 20.2)*† 1.0 (0.5 – 1.8) 1.1 (0.7 – 1.8)
‡ P < 0.05 between the three groups; * P < 0.05 vs G3; † P < 0.05 vs 
G2
NDBP = nocturnal diastolic BPCardiovascular Diabetology 2006, 5:19 http://www.cardiab.com/content/5/1/19
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cemic agents [24]. In both cross-sectional [25-27] and
prospective [28] studies a good correlation was shown
between FBG and HbA1. In addition, the retrospective
average of FBG values is considered a good index to estab-
lish a previous long-term glycemic control in patients with
type 2 DM [29]. Hence, it is unlikely that the lack of HbA1
values to evaluate previous glycemic control could have
influenced our results.
It has also been suggested that a poor glycemic control
could be responsible for the increase of NSBP levels [30].
In fact, in our study, we found a positive correlation
between these two variables. However, in our models of
multiple regression, only hypertension duration was an
independent predictor to NSBP. Furthermore, we found
that both hyperglycemia and NSBP were independent pre-
dictors to LVMI. These findings support the hypothesis
that hyperglycemia could not be directly responsible for
the increased NSBP in diabetic patients, although it could
have influenced on this parameter.
Autonomic neuropathy (AN) could be a via through
hyperglycemia would elevate NSBP levels. Some studies
have related AN to an increase of LVM [31] and to the loss
of nocturnal BP decrease [8]. In addition, we compared
normotensive diabetic patients with normal subjects and
found that a higher score of AN was already correlated to
a higher LVMI (data not published). AN could reduce the
nocturnal BP falls through the reduction of vagal tonus
and increase of cardiac output during sleep [21].
It has been described a correlation between hyperglyc-
emia and LVMI in diabetic patients [4,7] and some
authors have suggested mechanisms to explain how
hyperglycemia acts on cardiac mass [4]. Nevertheless, pro-
spective data evaluating the effect of a better glycemic con-
trol on LVM are rare [9]. The retrospective average of FBG
values is considered a good index to establish a previous
long-term glycemic control in patients with type 2 DM
[29]. Coutinho et al [32] have recently published a meta-
regression analysis of 20 studies including 95,783 nondi-
abetic individuals who had 3,707 cardiovascular events
and who were followed for 12.4 years. They showed that
high fasting glucose values increased the risk for cardio-
vascular events. Fasting glucose of 109 mg/dl increased
the risk of cardiovascular events by 1.33 compared with a
fasting glucose of 75 mg/dl. Therefore, it is obvious that
glucose level seems to be a risk factor for cardiovascular
events even within a range that is below the diabetic
threshold. Glucose is likely to be a continuous cardiovas-
cular risk factor, similar to cholesterol and blood pressure.
This study showed that diabetic patients with NSBP≥140
mmHg had a great increase on prevalence of LVH. In this
subgroup, when the average of FBG was >165 mg/dl, the
risk of LVH had an additional increment. These high val-
ues of FBG, that started to increase the risk of LVH, could
be explained by the longer diabetes duration. Further-
more, Staessen et al [33], in a meta-analysis of 23 studies,
including a total of 3,476 normal subjects, concluded that
only levels ≥137 mmHg for NSBP should be considered as
definite hypertension. This NSBP value is too close to the
level that we found to start increasing the risk of LVH.
The coexistence of LVH and possible ischemic heart dis-
ease is a well-known phenomenon in general population
and it has been suggested that ischemic heart disease is a
consequence rather than a cause of LVH [34]. In addition,
the findings of Ghali et al [35] and Fujita et al [36] suggest
that the contribution of ischemia to enlarge LVM is rather
small. We have not excluded silent ischemia, a condition
Risk of left ventricular hypertrophy and average of fasting  blood glucose values in the subgroup with nocturnal systolic  blood pressure ≥140 mmHg Figure 1
Risk of left ventricular hypertrophy and average of fasting 
blood glucose values in the subgroup with nocturnal systolic 
blood pressure ≥140 mmHg. LVMI – left ventricular mass 
index AFBG – average of fasting blood glucose LVH – left 
ventricular hypertrophy
50
75
100
125
150
175
60 75 90 105 120 135 150 165 180 195 210 225 240 255 270
LVH (+): n=15
LVH (-): n=12
ODDS RATIO= 11,0
p< 0,05
L
V
M
I
 
(
g
/
m
²
)
AFBG (mg/dL)
Table 4: Subgroup with NSBP≥140 mmHg divided according to 
the presence of LVH
Subgroup LVH + LVH -
N1 5 1 2
Age (years) 57 ± 9 60 ± 7
BMI (kg/m2) 28 ± 4 31 ± 4
Hypertension duration (months) 192 (36 – 420) 126 (18 – 612)
DM duration (months) 108 (6 – 360) 54 (8 – 312)
DSBP (mmhg) 169 ± 12 166 ± 22
NSBP (mmHg) 152 ± 10 157 ± 20
DDBP (mmHg) 102 ± 8 100 ± 10
NDBP (mmHg) 86 ± 8 88 ± 8
GCI (%) 29 (4 – 67)* 8 (0–75)
*P < 0.05Cardiovascular Diabetology 2006, 5:19 http://www.cardiab.com/content/5/1/19
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claimed to be frequently present in type 2 DM. Neverthe-
less, this claim is based on noninvasive methods revealing
a prevalence of ischemia in 36% [37] and 31% [38] of
patients with type 2 DM. In contrast, coronary angiogra-
phy only revealed prevalence of significant coronary
artery disease in 8% and 11% of the diabetic patients
included in the two above-mentioned studies, respec-
tively. Therefore, ischemic heart disease does not seem to
be an important contributor to the LVH in our patients.
It has been suggested that abnormalities in lipid metabo-
lism could be involved in the pathogenesis of diabetic car-
diomyopathy [5]. Nevertheless, we have recently
demonstrated that, in hypertensive patients with type 2
DM, the reversal of LVH can occur independently of any
variation on lipids levels [9].
Almost all of our diabetic patients were using anti-hyper-
tensive drugs for more than one year before the study.
Most of them were in use of ACE-inhibitors and calcium
antagonists, which are recognized efficients at LVH regres-
sion in hypertensive patients [39]. Hence, the kind of anti-
hypertensive used can not justify the higher LVMI in the
diabetic group.
Salmasi et al [40] described that in hypertensive patients,
left ventricular diastolic function is determined by LMVI
and the status of preclinical glucose intolerance. Our
study found a strong relation between NSBP and LVMI
and no relation between NSBP and diastolic function,
what suggests that the worse diastolic function in our dia-
betic hypertensive patients could be caused by a higher
LVMI. Some authors have also found a worse diastolic
function in diabetics and some of them considering these
abnormalities as largely irreversible [3,6,41]. Although we
have not observed a correlation between NSBP and
diastolic function, a intensive control of nocturnal presso-
ric overload might contribute to an improvement of this
function through a possible reversal of LVH.
Aepfelbacher et al [42] have described interventricular
septal thickness decrease and left ventricular mass regres-
sion in type 1 diabetic patients with improved glycemic
control. They have not found any BP variation evaluated
by ABPM during their study. Nevertheless, a small
number of patients were evaluated and LVM was also not
adjusted by body surface area to calculate left ventricular
mass index, that is the best parameter to evaluate cardiac
hypertrophy. Moreover, type 2 diabetic patients also
present other confounders (lipid levels, aterosclerosis dis-
ease, arterial hypertension, obesity) that may influence
the results.
A BP overload, detectable by ambulatory recording and
not by clinic measurements, may be a major determinant
of left ventricular diastolic dysfunction and left ventricular
mass increase [43]. Our study reinforces the existence of a
specific cardiomyopathy related to DM where higher
NSBP levels and hyperglycemia should be co-factors for
an increased prevalence of LVH. The benefits of an inten-
sive control of NSBP in hypertensive patients with type 2
DM need to be clarified, what will be only possible if we
include ABPM in the routine exams of all type 2 diabetic
patients.
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